Intra-Cellular Therapies (NASDAQ:ITCI) Stock Rating Lowered by Mizuho

Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by equities research analysts at Mizuho from an “outperform” rating to a “neutral” rating in a report released on Monday,Briefing.com Automated Import reports. They presently have a $132.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $140.00. Mizuho’s price target suggests a potential upside of 2.64% from the stock’s current price.

Other analysts have also issued reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. StockNews.com began coverage on Intra-Cellular Therapies in a research report on Monday. They issued a “hold” rating for the company. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

NASDAQ ITCI opened at $128.60 on Monday. Intra-Cellular Therapies has a 52 week low of $62.78 and a 52 week high of $128.77. The business’s fifty day simple moving average is $110.27 and its 200-day simple moving average is $89.84. The firm has a market cap of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Research analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ITCI. Accredited Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the fourth quarter worth $28,000. True Wealth Design LLC purchased a new position in Intra-Cellular Therapies in the third quarter worth $32,000. GAMMA Investing LLC raised its position in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in Intra-Cellular Therapies in the third quarter worth $74,000. Finally, Venturi Wealth Management LLC purchased a new position in Intra-Cellular Therapies in the fourth quarter worth $96,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.